Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, grant of warrants in Genmab A/S29 Jun 2002
Genmab, Genmab publishes offering memorandum17 Jun 2002
Genmab, to present HuMax-CD4 safety data to date at EULAR11 Jun 2002
Genmab, presentation of Genmab10 Jun 2002
Genmab, Roche and Genmab announce major expansion of antibody collaboration6 Jun 2002
Genmab, capital increase in Genmab - directed offering6 Jun 2002
Genmab, correction to earlier announcement - pargraph 4 to DKK 158 million total6 Jun 2002
Genmab, capital increase - clarification of number of shares issued
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
6 Jun 2002
Genmab, Genmab completes accrual in HuMax-IL15 phase I/II-study30 May 2002
Genmab, GENMAB AND ACE BIOSCIENCES COLLABORATE TO TREAT INFECTIOUS DISEASE13 May 2002
Genmab, appoints VP manufacturing29 Apr 2002
Genmab, 1st quarterly report 200215 Apr 2002
  • Previous
  • 1
  • More pages
  • 152
  • 153
  • 154
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863